Allarity Therapeutics(ALLR)
$0.87+0.03 (+3.69%)
ALLR
Allarity Therapeutics stock drug pipeline
$0.87
At close:+0.03 (+3.69%)
Want to see ALLR full AI Analyst Report?
Allarity Therapeutics (ALLR) Drug Pipeline
374 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| 2X-121 And Dovitinib | Advanced Solid Tumors | Phase I | Suspended | Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors | Oct 05, 2022 | ― |
| Ixabepilone Injection | Metastatic Breast Cancer | Phase II | Suspended | Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP. | Mar 08, 2021 | ― |
| 2X-121 | Advanced Ovarian Cancer | Phase II | Recruiting | Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer | Mar 08, 2019 | ― |
| Irofulven, Prednisolone 10 Mg | Metastatic Castration-Resistant Prostate Cancer Patients | Phase II | Completed | Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®) | Aug 21, 2018 | ― |
| Parp Inhibitor 2X-121 | Metastatic Breast Cancer | Phase II | Completed | Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP | Apr 26, 2018 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| 2X-121 And Dovitinib | Phase I | Advanced Solid Tumors | Suspended | Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors | Oct 05, 2022 | ― |
| Ixabepilone Injection | Phase II | Metastatic Breast Cancer | Suspended | Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP. | Mar 08, 2021 | ― |
| 2X-121 | Phase II | Advanced Ovarian Cancer | Recruiting | Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer | Mar 08, 2019 | ― |
| Irofulven, Prednisolone 10 Mg | Phase II | Metastatic Castration-Resistant Prostate Cancer Patients | Completed | Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®) | Aug 21, 2018 | ― |
| Parp Inhibitor 2X-121 | Phase II | Metastatic Breast Cancer | Completed | Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP | Apr 26, 2018 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Allarity Therapeutics, Inc. (ALLR) have in its pipeline
Allarity Therapeutics ALLR is currently developing the following drugs: 2X-121 And Dovitinib, Ixabepilone Injection, 2X-121, Irofulven, Prednisolone 10 Mg, Parp Inhibitor 2X-121. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

